Biosimilar Primer: US Physicians’

Attitudes, Beliefs, and Intentions

Info@ISRreports.com

©2014 Industry Standard Research www.ISRreports.com

PREVIEW

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 2

act with confidence

Report Overview

This report features survey data portraying the perspectives of US physicians (cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists) regarding their familiarity and prescription propensity for biosimilar products. This is not ISR’s first report on the views that US physicians hold regarding biosimilars. In comparison to our 2013 Biosimilar Primer report, physician familiarity with biosimilars has increased. With this data, biopharmaceutical companies, payers, and service providers can make more informed decisions regarding product marketing, delivery, and manufacturing.

28Charts and Graphs

173Respondents

31Pages

Executive summary

Familiarity with biosimilars

Prescribing and pricing • Medicine identification • Likelihood of prescribing a recently approved biosimilar • Discount required for physician recommendation

Switching and DAW preference• Importance of being notified of pharmacy-level substitution• Opinion on EU ban on pharmacy-level substitution • Expected biologic prescriptions to be written with a DAW clause• Likelihood to use DAW clause• Preferred clinical testing for biosimilars

Demographics

Report Structure:

Respondent Demographics:

What you will learn in this report:ISR’s report surveyed board certified cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists in the U.S. to gain insight into:

• The level of familiarity physicians have with biosimilars

• Intentions for prescribing based on biosimilar pricing

• Opinions of pharmacy switching

• Beliefs on the required clinical development process for biosimilar approval

173

Number of Participants Area of Board Certification Practice Type

Physician-owned private practice: 58%

Large physician-owned group practice: 23%

Integrated patient/hos-pital network: 19%

Cardiology (N=30)

Neurology (N=32)

Oncology (N=32)

Primary Care (N=48)

Pulmonology (N=31)

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 3

act with confidence

Familiarity with Biosimilars

Prescribing and Pricing

Medicine Identification - Understand how physicians identify medicines when writing a prescription (i.e. by brand name, generic name, or NDC number)

Biosimilar vs. The Original Compound - Prescribing Likelihood – If a payer recommends a biosimilar (via reimbursement levels), how likely would a physician be to prescribe the biosimilar vs. the original compound?

Pricing of Biosimilar Products – What pricing expectations do physicians have for biosimilars? At what price would a physician recommend a biosimilar product over the original compound?

Switching and DAW Preferences

Importance of Pharmacy Notification if Different Drug Dispensed – How important is it that physicians are notified by the pharmacist when a patient receives a biologic medicine other than the one prescribed?

Opinion on EU ban on Pharmacy-level Substitution — Many EU countries have mandated that there can be no pharmacy-level substitution for biosimilar products. What do physicians think of this ban?

Pharmacy Level Substitutions – Understand physicians’ thoughts on pharmacy-level substitutions for biosimilar products.

When to Use DAW Clause – How do physicians use the DAW clause differently when prescribing chemical and biological products?

Frequency of DAW Prescriptions Written for Biosimilars – How often will physicians write the “DAW” clause for biologics with a biosimilar option?

Preferred Clinical Testing for Biosimilars — Do physicians think biosimilars should have full-fledged clinical trials or follow chemical generics and just require pharmacodynamics, pharmacokinetic, and bioequivalence testing?

More Concerned about Safety or Efficacy — Are physicians most concerned with a new biosimilar product’s safety, efficacy, or neither?

Report Contents

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 4

act with confidence

Table of Contents

For full table of contents and additional sample pages, please download the full preview from ISR’s website: http://www.isrreports.com/product/biosimilar-primer-us-physicians-atti-tudes-beliefs-and-intentions/

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 5

act with confidence

act with confi dence

Introduction

www.ISRreports.com ©2014 | Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 4

IntroductionAs the old adage goes, the only certainties in life are: death, taxes, and increased biosimilar commercialization. The following are examples of biosimilar activity taken from pharmaceutical industry publications during a two week period in April, 2014.

• Boehringer Ingelheim’s chairman stated, “We see biosimilars as a future growth fi eld.” BI’s most advanced biosimilar is a version of Sanofi ’s insulin Lantus, which is being developed in partnership with Lilly and is currently undergoing regulatory review in Europe with a view to launch some point this year in the region. A US launch is planned for 2015.

• Epirus Pharmaceuticals raised $36M to fund its biosimilar work, with a lead Phase III program for a Remicade knockoff along with follow-up programs for Humira and Avastin. Epirus’ strategy is to launch biosimilars outside of the US and Europe in hopes of improving their changes with local regulators while gaining government support to build facilities and win government contracts for lower-priced therapies.

• Baxter is teaming up with Coherus BioSciences to develop a copy of Amgen and Pfi zer’s Enbrel with plans to fi le for FDA approval in 2016.

• Hospira persuaded a U.K. court to overturn two Herceptin patents, which means biosimilar competition could arise there at any time.

• Catalent signed a deal to lend its biologics development technology to China’s Zhejang Hisun Pharmaceuticals. Under the agreement Catalent will supply the technology to develop biosimilars of Remicade, Humira, and Lemtrada. Catalent says its system can get biologics projects into the clinic three times faster than other approaches.

• France passed a law that gives pharmacists the ability to substitute biosimilar drugs for the original. It only applies to patients who are starting a new course of treatment and who are getting products from retail pharmacies (not hospitals) and still allows the physicians to demand the original biologic product.

• Japanese drugmaker Kyowa Hakko Kirin, who is partnering with Fuji to develop biosimilars, just fi nished construction on a new biologics plant and should be ready for operations in 1H2016.

This report features survey data concerning the perspectives of US physicians (cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists) regarding their familiarity and prescription propensity for biosimilar products. This is not ISR’s fi rst report on the views that US physicians hold regarding biosimilars. In comparison to our 2013 Biosimilar Primer report, physician familiarity with biosimilars has increased. While the two research endeavors don’t exactly match in

Sample Page

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 6

act with confidence

Sample Page

For full table of contents and additional sample pages, please download the full preview from ISR’s website: http://www.isrreports.com/product/biosimilar-primer-us-physicians-atti-tudes-beliefs-and-intentions/

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 7

act with confidence

Ordering Information

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.   For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.

About Industry Standard Research

Save on this, or any ISR report, by

registering a free account

Register now• Receive a $250 instant credit towards any ISR report• Earn 10% credit towards all future purchases• Receive advanced notifications on ISR’s latest reports and free resources

For pricing and ordering information, please visit: http://www.isrreports.com/product/biosimilar-primer-us-physicians-atti-tudes-beliefs-and-intentions/

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 8

act with confidence

www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 8

act with confidence

www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 10

act with confidence

www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10

act with confidence

The ISR DifferenceCustom-quality syndicated market research

www.ISRreports.com

ISR's Reports The Common Syndicated Reportvs.

How confident are you?

vs.Data Collection

ISR's proprietary data collection tools and channels support fast,

high quality data collection

Struggle to recruit the right targets and enough of them

vs.Sample Sizes

Robust sample sizes that instill confidence

Often insufficient industry representation that leaves you

defending results

vs.vs.Research methods

Mostly primary research;

always appropriate for the topic

One size fits all; usually publically

available data

vs.vs.Respondents

Sophisticated screening ensures genuine decision-makers

Undisclosed methodologies and

respondent demographics

vs.vs.Analysts

Decades of experience means more insights that are

immediately usable

Junior analysts capable of reporting numbers